» Articles » PMID: 35948785

The Glymphatic System: Implications for Drugs for Central Nervous System Diseases

Overview
Specialty Pharmacology
Date 2022 Aug 10
PMID 35948785
Authors
Affiliations
Soon will be listed here.
Abstract

In the past decade, evidence for a fluid clearance pathway in the central nervous system known as the glymphatic system has grown. According to the glymphatic system concept, cerebrospinal fluid flows directionally through the brain and non-selectively clears the interstitium of metabolic waste. Importantly, the glymphatic system may be modulated by particular drugs such as anaesthetics, as well as by non-pharmacological factors such as sleep, and its dysfunction has been implicated in central nervous system disorders such as Alzheimer disease. Although the glymphatic system is best described in rodents, reports using multiple neuroimaging modalities indicate that a similar transport system exists in the human brain. Here, we overview the evidence for the glymphatic system and its role in disease and discuss opportunities to harness the glymphatic system therapeutically; for example, by improving the effectiveness of intrathecally delivered drugs.

Citing Articles

Cortical Morphology Alterations Mediate the Relationship Between Glymphatic System Function and the Severity of Asthenopia.

Chen Y, Xu J, Kong Y, Kang Y, Gong Z, Wang H Int J Biomed Imaging. 2025; 2025:4464776.

PMID: 40041480 PMC: 11879604. DOI: 10.1155/ijbi/4464776.


The sentinel against brain injury post-subarachnoid hemorrhage: efferocytosis of erythrocytes by leptomeningeal lymphatic endothelial cells.

Deng H, Xu Y, Wu K, Li Y, Zhang Y, Yu H Theranostics. 2025; 15(6):2487-2509.

PMID: 39990222 PMC: 11840724. DOI: 10.7150/thno.103701.


Glymphatic dysfunction exacerbates cognitive decline by triggering cortical degeneration in Parkinson's disease: evidence from diffusion-tensor MRI.

Zhao Y, Xu C, Chen Y, Gong T, Zhuo M, Zhao C Brain Commun. 2025; 7(1):fcaf029.

PMID: 39980740 PMC: 11840164. DOI: 10.1093/braincomms/fcaf029.


Perivascular and parenchymal brain fluid diffusivity in patients with a recent small subcortical infarct.

Rudilosso S, Munoz-Moreno E, Laredo C, Calvet A, Rodriguez-Vazquez A, Girona A Neuroradiology. 2025; .

PMID: 39853343 DOI: 10.1007/s00234-025-03546-9.


Insights into glymphatic system dysfunction and glucose continuum.

Velikova T, Vasilev G World J Diabetes. 2024; 15(12):2404-2408.

PMID: 39676799 PMC: 11580585. DOI: 10.4239/wjd.v15.i12.2404.


References
1.
Banks W . From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016; 15(4):275-92. DOI: 10.1038/nrd.2015.21. View

2.
Terstappen G, Meyer A, Bell R, Zhang W . Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov. 2021; 20(5):362-383. DOI: 10.1038/s41573-021-00139-y. View

3.
Calias P, Banks W, Begley D, Scarpa M, Dickson P . Intrathecal delivery of protein therapeutics to the brain: a critical reassessment. Pharmacol Ther. 2014; 144(2):114-22. DOI: 10.1016/j.pharmthera.2014.05.009. View

4.
Brochner C, Holst C, Mollgard K . Outer brain barriers in rat and human development. Front Neurosci. 2015; 9:75. PMC: 4360706. DOI: 10.3389/fnins.2015.00075. View

5.
Soderquist R, Mahoney M . Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics. Expert Opin Drug Deliv. 2010; 7(3):285-93. PMC: 4068128. DOI: 10.1517/17425240903540205. View